04.04.2016Anergis closes CHF 5 million financing round extension
You are here
NewsAnergis closes CHF 5 million financing round extension
Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it has closed a CHF 5 million financing round extension with existing investors. In addition, the Company is preparing a Phase IIb clinical trial with its lead compound AllerT in patients with birch pollen allergy. The study is designed as a multicenter, double-blind, placebo-controlled, randomized trial to assess the efficacy and tolerability of two dosing regimens of AllerT In Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis (ATIBAR). ATIBAR is expected to start in fall 2016. With a total of 450 patients, ATIBAR will be the largest field-based trial conducted so far with an ultra-fast allergy treatment for tree allergy.
Most
importantly, the ATIBAR trial is designed as a confirmatory efficacy
trial with the statistical power necessary to meet both European and US
FDA efficacy criteria for allergy immunotherapy products. Results will
be expected in the third quarter of 2017.
“Our
exploratory dose ranging trial with AllerT provided us with excellent
new safety, tolerability and immunogenicity data. We are now preparing
the ATIBAR trial as a confirmatory efficacy trial of the 50 µg dose and
to verify that 10 µg is the lowest effective dose of AllerT,“ said Kim
Simonsen, Chief Development Officer of Anergis.
"Thanks to the continued support of our investors, we have complemented our last financing round with a CHF 5 million extension and are now preparing AllerT for its future registration. Following a successful completion of the ATIBAR trial, we expect that only one more confirmatory efficacy Phase III trial will be required before registration,” added Vincent Charlon, Chief Executive Officer of Anergis.
